Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2021 May 25;30(160):210026.
doi: 10.1183/16000617.0026-2021. Print 2021 Jun 30.

Patient-reported outcomes and patient-reported outcome measures in interstitial lung disease: where to go from here?

Meena Kalluri  1   2 , Fabrizio Luppi  3   2 , Ada Vancheri  4 , Carlo Vancheri  5 , Elisabetta Balestro  6 , Francesco Varone  7 , Nesrin Mogulkoc  8 , Giulia Cacopardo  9 , Elena Bargagli  10 , Elizabeth Renzoni  11 , Sebastiano Torrisi  5 , Mariarosaria Calvello  7 , Alessandro Libra  4 , Mauro Pavone  5 , Francesco Bonella  12 , Vincent Cottin  13   14 , Claudia Valenzuela  15   2 , Marlies Wijsenbeek  16   2 , Elisabeth Bendstrup  17   2 ; 3rd International Summit for ILD (ISILD), Erice collaborators listed below
Collaborators, Affiliations
Review

Patient-reported outcomes and patient-reported outcome measures in interstitial lung disease: where to go from here?

Meena Kalluri et al. Eur Respir Rev. .

Abstract

Patient-reported outcome measures (PROMs), tools to assess patient self-report of health status, are now increasingly used in research, care and policymaking. While there are two well-developed disease-specific PROMs for interstitial lung diseases (ILD) and idiopathic pulmonary fibrosis (IPF), many unmet and urgent needs remain. In December 2019, 64 international ILD experts convened in Erice, Italy to deliberate on many topics, including PROMs in ILD. This review summarises the history of PROMs in ILD, shortcomings of the existing tools, challenges of development, validation and implementation of their use in clinical trials, and the discussion held during the meeting. Development of disease-specific PROMs for ILD including IPF with robust methodology and validation in concordance with guidance from regulatory authorities have increased user confidence in PROMs. Minimal clinically important difference for bidirectional changes may need to be developed. Cross-cultural validation and linguistic adaptations are necessary in addition to robust psychometric properties for effective PROM use in multinational clinical trials. PROM burden of use should be reduced through appropriate use of digital technologies and computerised adaptive testing. Active patient engagement in all stages from development, testing, choosing and implementation of PROMs can help improve probability of success and further growth.

PubMed Disclaimer

Conflict of interest statement

Conflict of interest: M. Kalluri reports grants and personal fees from Boehringer Ingelheim, and Roche, outside the submitted work. Conflict of interest: F. Luppi reports grants and lecture fees from Roche and lecture fees from Boehringer Ingelheim. Conflict of interest: A. Vancheri has nothing to disclose. Conflict of interest: C. Vancheri reports grants and personal fees from Roche and Boehringer Ingelheim, outside the submitted work. Conflict of interest: E. Balestro reports personal fees from Roche and Boehringer Ingelheim, outside the submitted work. Conflict of interest: F. Varone reports unrestricted grants, consultancy and lecture fees from Roche and Boehringer Ingelheim. Conflict of interest: N. Mogulkoc has nothing to disclose. Conflict of interest: G. Cacopardo has nothing to disclose. Conflict of interest: E. Bargagli has nothing to disclose. Conflict of interest: E. Renzoni reports grants from Boeringher Ingelheim, and lecture fees from Boeringher Ingelheim and Roche, outside the submitted work. Conflict of interest: S. Torrisi reports personal fees from Hoffman La-Roche and Boehringer Ingelheim, outside the submitted work. Conflict of interest: M. Calvello has nothing to disclose. Conflict of interest: A. Libra has nothing to disclose. Conflict of interest: M. Pavone has nothing to disclose. Conflict of interest: F. Bonella reports grants and personal fees from Boehringer Ingelheim and Roche, and consultancy fees from BMS, Galapagos, GSK and Savara, outside the submitted work. Conflict of interest: V. Cottin reports personal fees and non-financial support from Actelion and Roche/Promedior; grants, personal fees and non-financial support from Boehringer Ingelheim; and personal fees from Bayer/MSD, Novartis, Sanofi, Celgene/BMS, Galapagos, Galecto, Shionogi, AstraZeneca and Fibrogen, outside the submitted work. Conflict of interest: C. Valenzuela reports personal fees from Boehringer Ingelheim, F. Hoffmann-La Roche, Galapagos and BMS, outside the submitted work. Conflict of interest: M. Wijsenbeek reports grants and other funding from Boehringer Ingelheim and Hoffman-La Roche, and other funding from Respivant, Galapagos, Novartis and Savara, outside the submitted work. All fees and grants were paid to her institution. Conflict of interest: E. Bendstrup reports grants and personal fees from Boehringer Ingelheim and Hoffmann-La Roche, and personal fees from Galapagos and AstraZeneca, outside the submitted work.

Figures

FIGURE 1:
FIGURE 1:
Comprehensive outcomes assessment in interstitial lung disease (ILD)/idiopathic pulmonary fibrosis/progressive fibrotic ILD. HRQoL: health-related quality of life; PESaM: patient experience and satisfaction with medication.
FIGURE 2:
FIGURE 2:
Development of patient-reported outcome measures (PROMs). MCID: minimal clinically important difference. Adapted from US Food and Drink Administration guidance on the development of a PROM instrument for drug development to support labelling claims [80].
See this image and copyright information in PMC

References

    1. Wijsenbeek M, Cottin V. Spectrum of fibrotic lung diseases. N Engl J Med 2020; 383: 958–968. doi:10.1056/NEJMra2005230 - DOI - PubMed
    1. Swigris JJ, Stewart AL, Gould MK, et al. . Patients’ perspectives on how idiopathic pulmonary fibrosis affects the quality of their lives. Health Qual Life Outcomes 2005; 3: 61. doi:10.1186/1477-7525-3-61 - DOI - PMC - PubMed
    1. van Manen MJG, Geelhoed JJM, Tak NC, et al. . Optimizing quality of life in patients with idiopathic pulmonary fibrosis. Ther Adv Respir Dis 2017; 11: 157–169. doi:10.1177/1753465816686743 - DOI - PMC - PubMed
    1. International Alliance of Patients’ Organizations (IAPO) . What is Patient-Centred Healthcare? A Review of Definitions and Principles. 2007, London, IAPO.
    1. Ferrara G, Luppi F, Birring SS, et al. . Best supportive care for idiopathic pulmonary fibrosis: current gaps and future directions. Eur Respir Rev 2018; 27: 170076. doi:10.1183/16000617.0076-2017 - DOI - PMC - PubMed

MeSH terms